Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.
The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the economic burden to the health service of metabolic syndrome (MetS) in patients with hypertension and its consequences, in three European countries in 2008, and to forecast future economic burden in 2020 using projected demographic estimates and assumptions around the growth of MetS. An age-, sex- and risk group-structured prevalence-based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define MetS. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy. The economic burden to the health service of MetS in patients with hypertension has been estimated at 24,427 euro, 1,900 euro and 4,877 euro million in Germany, Spain and Italy, and is forecast to rise by 59, 179 and 157%, respectively, by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with MetS compared to those without and rose incrementally with the additional number of MetS components present. In conclusion, the presence of MetS in patients with hypertension significantly inflates economic burden, and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of MetS.
Wille
Eberhard
E
Fakultät für Volkswirtschaftslehre, L 7, 3-5, 2. OG, Raum 21, 68131, Mannheim, Germany. wille@uni-mannheim.de
Scholze
Jürgen
J
Alegria
Eduardo
E
Ferri
Claudio
C
Langham
Sue
S
Stevens
Warren
W
Jeffries
David
D
Uhl-Hochgraeber
Kerstin
K
D002318:Cardiovascular Diseases / Q000150:complications / Q000191:economics / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000191:economics / Q000517:prevention & control; D005858:Germany / Q000453:epidemiology; D005102:Health Expenditures; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000191:economics* / Q000453:epidemiology; D007558:Italy / Q000453:epidemiology; D024821:Metabolic Syndrome / Q000150:complications* / Q000453:epidemiology; D018803:Models, Economic; D015995:Prevalence; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
Blood Press. 2007;16(6):347-53
18058454
Am J Med. 2006 Oct;119(10):812-9
17000207
Obes Res. 2004 Feb;12(2):173-9
14981208
J Hypertens. 2008 Sep;26(9):1801-8
18698215
J Hypertens. 2006 May;24(5):837-43
16612244
J Cardiometab Syndr. 2007 Winter;2(1):9-15
17684454
Eur Heart J. 2007 Jun;28(12):1462-536
17562668
Int J Clin Pract. 2005 Jun;59(6):632-8
15924589
J Hypertens. 2008 Oct;26(10):1891-900
18806611
Am J Cardiol. 2008 Aug 15;102(4):424-8
18678299
Am J Hypertens. 2006 Feb;19(2):189-96; discussion 197-8
16448891
Atherosclerosis. 2008 Mar;197(1):147-53
17466306
Curr Med Res Opin. 2007 Mar;23(3):495-503
17355731
Circulation. 2002 Dec 17;106(25):3143-421
12485966
Annu Rev Nurs Res. 2000;18:48-90
10918932
BMC Public Health. 2008 Jun 05;8:200
18533989
Am J Hypertens. 2007 May;20(5):558-64
17485022
Blood Press. 2009;18(6):308-47
20001654
JAMA. 2003 May 14;289(18):2363-9
12746359
J Hypertens. 2007 Jul;25(7):1491-8
17563573
Blood Press. 2007;16(1):20-7
17453748
J Hum Hypertens. 2007 Oct;21(10):795-801
17508012
Lancet. 2007 Jan 20;369(9557):201-7
17240286
Med Clin (Barc). 2006 Mar 25;126(11):406-9
16595083
J Hypertens. 1998 Aug;16(8):1103-12
9794712
Diabetes Care. 2005 Jul;28(7):1769-78
15983333
Metab Syndr Relat Disord. 2009 Aug;7(4):305-14
19558267
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
17258085
CMAJ. 1999 Jan 12;160(1):31-7
9934341
Health Policy. 2007 Oct;83(2-3):257-67
17335933
Diabetologia. 2002 Jul;45(7):S5-12
12136405
Rev Esp Cardiol. 2008 Oct;61(10):1030-40
18817679
Stroke. 1998 Jan;29(1):244-50
9445358
Diabetes Care. 2005 Sep;28(9):2289-304
16123508
Circulation. 2004 Nov 2;110(18):2968-75
15520336
Diabetes Care. 2001 Apr;24(4):683-9
11315831
Pharmacoeconomics. 2004;22(15):1001-14
15449964
J Hum Hypertens. 1992 Dec;6(6):481-3
1296013
Blood Press. 2004;13(2):80-8
15182110
Int J Clin Pharmacol Ther. 2010 Mar;48(3):173-83
20197011
J Hypertens. 2004 Jan;22(1):51-7
15106794
J Hypertens. 2008 Apr;26(4):819-24
18327094
J Hypertens. 2005 Nov;23(11):2093-100
16208153
Ann Rheum Dis. 2004 Apr;63(4):395-401
15020333
Hypertension. 2007 Jan;49(1):40-7
17130308
Blood Press. 2002;11(1):35-45
11926349
Am J Hypertens. 2007 Dec;20(12):1291-6
18047919
Diabetes Care. 2007 Oct;30(10):2553-8
17623825
Stroke. 2009 Jan;40(1):200-5
18927451
J Hypertens. 2001 Jan;19(1):149-55
11204296
Am J Med. 2006 May;119(5 Suppl 1):S24-30
16563944
Curr Med Res Opin. 2008 Jan;24(1):121-7
18031596
J Clin Hypertens (Greenwich). 2007 Aug;9(8):595-600
17673880
J Hypertens. 2008 Oct;26(10):2064-70
18806632
J Clin Hypertens (Greenwich). 2004 Feb;6(2):76-84
14872145
J Am Coll Cardiol. 2004 May 19;43(10):1817-22
15145106
Circulation. 2003 Jul 29;108(4):414-9
12860911
J Hum Hypertens. 2007 May;21(5):366-73
17301825